PREVENT: going beyond current paradigms for breast cancer risk assessment
Breast cancer is a major public health concern and early detection might allow both less aggressive care and higher expectation of cure. Screening for breast cancer through mammography is well accepted in most countries. Because screening mammography is less effective among younger women, the cost effectiveness models have suggested a threshold of 50 years old to begin the screening program. On the other hand, a substantial proportion of breast cancers occurs in women between the ages of 40 and 55. There is a medical need to identify women at higher risk of breast cancer.
This webinar will describe PREVENT, the new solution developed by SOPHiA GENETICS, that incorporates genetic and non-genetic risk factors into a simple to use test. PREVENT provides physicians with a more precise estimation of breast cancer risk and supports personalized screening plans and preventive measures.
In the first part of the webinar, Dr. David Cox, the SOPHiA GENETICS’ Clinical Application Product Manager who has developed PREVENT, will cover the scientific background and technical details of this breast cancer risk assessment test.
Then, Pr. Xavier Pivot, General Director of the Paul Strauss Center, will describe the clinical utility of PREVENT, and how it will fit into the breast cancer program at the Paul Strauss Center.
Prof. Xavier Pivot
General Director - Paul Strauss Center, Strasbourg
Professor Xavier Pivot was awarded his MD - Ph.D. from the French University of Nice and Marseille in 1995 and 1997, respectively. In 2017, he was appointed General Director of the Paul Strauss Center and Regional Institute of Cancer in Strasbourg. Professor of Medical Oncology since 2002, he was previously Head of the Department of Oncology at the University Hospital Jean Minjoz (Besançon – Bourgogne Franche Comte). He is past member of Anti-Cancer Therapy Commission for the French Medicine Agency. He was Lead of the Breast Research Group at the French National Cancer Institute (INCa) from 2005 and 2012. His 240 publications reflect his interest in breast cancer research and treatment, especially in HER2-positive breast tumour.
Dr. David Cox holds a Ph.D. in Human Genetics from the University of Turin, and an MS in Epidemiology from the Harvard School of Public Health. Dr. Cox has spent his academic career examining the contribution of common genetic variants to breast cancer risk and response to treatment through his work in the Nurses Health Studies, the Breast and Prostate Cancer Cohort Consortium, and the SIGNAL/PHARE and SToRM clinical cohorts. He joined SOPHiA GENETICS in 2017 to transfer his decades of research in genetic epidemiology into solutions accessible to physicians.
Global leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company which has developed SOPHiA Artificial Intelligence (AI), the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients.
The global network of over 850 institutions from 77 countries that use the SOPHiA DDM® analytical platform powered by SOPHiA form the world’s largest clinical genomics community.
By enabling the rapid adoption of genomic testing worldwide, turning data into actionable clinical insights, and sharing knowledge through its community, SOPHiA GENETICS is democratizing Data-Driven Medicine to help save lives.